Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$148.36−1.16 (-0.78%)
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Invanz (ertapenem, legacy) by Year
Invanz (ertapenem, legacy) — U.S. reported growth YoY (%) (%)
Merck Invanz (ertapenem, legacy): -157.0% in FY2021. No newer figure appears in the documents we track.
Latest, FY2021
-157.0%
Period ended Dec 31, 2021
Change on a year earlier
–
History
4 years
Since FY2017
Sources
4
Documents cited below
Where the FY2021 figure comes from
“|| Invanz | 202 | 211 | -4 | (5 | ) | 9 | -157 | 207 | 202 | 3”
Source: Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Reported in Form 8-K Table 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Invanz (ertapenem, legacy) — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2021 | Dec 31, 2021 | -157.0% | – | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2019 | Dec 31, 2019 | -88.0% | -58.0 pts | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2018 | Dec 31, 2018 | -30.0% | -40.0 pts | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2017 | Dec 31, 2017 | 10.0% | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Cite this data
StockData. (2026). Merck Invanz (ertapenem, legacy) (%), annual FY2017–FY2021 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-invanz-us-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.